Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Biosimilar in Pediatric SSNS
NCT05850546Phase 3Not yet recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Mar 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in nephrotic syndrome, sponsored by Children's Hospital of Fudan University. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT05850546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850546.